NL-OMON26111
Recruiting
Not Applicable
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.
VU University Medical Center Amsterdam0 sites22 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- VU University Medical Center Amsterdam
- Enrollment
- 22
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. First diagnosis of Burkitt lymphoma, histological confirmed according to the WHO classification 2008;
- •2\. Age ≥ 18 years;
Exclusion Criteria
- •1\. All histopathological diagnoses other than BL according to the WHO classification 2008, irrespective of the presence of MYC rearrangement;
- •2\. Inadequate renal function or creatinine clearance \< 50 ml/min unless lymphoma related;
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): A phase II trial.Advanced previously untreated Chronic Lymphocytic LeukemiaNL-OMON23278Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedP.O. box 52013008 AE RotterdamTel: +31 10 7041560Fax: +31 10 7041028e-mail: hdc@erasmusmc.nl62
Completed
Phase 2
Efficacy and feasibility of first-line treatment with risk-adapted dose-adjusted EPOCH-R (DA-EPOCH-R) in patients with Burkitt lymphoma. A phase II clinical trial.Burkitt lymphomahighly aggressive B cell lymphoma10025320NL-OMON36941Vrije Universiteit Medisch Centrum22
Active, not recruiting
Not Applicable
A trial to investigate treatment with EPOCH-R in patients with Burkitt lymphoma, by adapting the dose to the risk classification of the disease.Burkitt lymphomaMedDRA version: 14.1Level: HLTClassification code 10006596Term: Burkitt's lymphomasSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-003141-16-NLVU University Medical Center
Not yet recruiting
Phase 2
First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal CancerEfficacy, SelfSafety IssuesColo-rectal CancerNCT06491355Sir Run Run Shaw Hospital72
Unknown
Not Applicable
Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLCEffect IncreasedSafety IssuesNCT04360655Shanghai Pulmonary Hospital, Shanghai, China50